AZN News
AstraZeneca PLC
$184.11
-$1.37(-0.74%)
78
Overall
95
Value
75
Tech
65
Quality
Market Cap
$287.39B
Volume
297.77K
52W Range
$153.41 - $212.71
Target Price
$212.77
AZN news: the latest AstraZeneca PLC headlines, press releases and market updates, newest first.
Latest AZN News
- AstraZeneca’s Reported $10 Billion Rhythm Bid Raises the Stakes for Palatin’s Obesity Pipeline (NASDAQ: PTN)Newswire TipRanks · Nov 11, 2026
- AstraZeneca Builds Hong Kong Breast Cancer Evidence in New Real-World StudyTipRanks Clinical-Trials-Auto-Generated Newsdesk · Nov 4, 2026
- AstraZeneca Updates AZD4144 Drug-Interaction Study: What Investors Need to KnowTipRanks Clinical-Trials-Auto-Generated Newsdesk · Nov 3, 2026
- Citi Sticks to Its Buy Rating for AstraZeneca (AZN)TipRanks Auto-Generated Intelligence Newsdesk · Nov 2, 2026
- AstraZeneca (AZN) Gets a Buy from Bank of America SecuritiesTipRanks Auto-Generated Intelligence Newsdesk · Oct 31, 2026
- AstraZeneca’s SELENE 1 Trial Positions AZD6234 in the Obesity Drug RaceTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 30, 2026
- 2 Strong Buy Healthcare Stocks with Glowing Q3 Earnings – BTSG, AZN.David Craik · Oct 30, 2026
- 2 Strong Buy Healthcare Stocks with Glowing Q3 Earnings – BTSG, AZN.David Craik · Oct 30, 2026
- AstraZeneca Expands Rare Disease Footprint With New HPP Study in ChinaTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 29, 2026
- AstraZeneca’s SELENE 2 Trial Puts AZN Deeper Into the Obesity–Diabetes RaceTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 28, 2026
- Citi Sticks to Their Buy Rating for AstraZeneca (AZN)TipRanks Auto-Generated Intelligence Newsdesk · Oct 28, 2026
- AstraZeneca’s QUARTZ Study Shines New Light on Real-World Asthma Rescue ChoicesTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 26, 2026
- AstraZeneca Expands Selumetinib’s Real-World Footprint With New NF1 Study in ChinaTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 22, 2026
- AstraZeneca (AZN) Receives a Buy from J.P. MorganTipRanks Auto-Generated Intelligence Newsdesk · Oct 21, 2026
- AstraZeneca Builds Real-World Kidney Data in China, Signaling Long-Term Growth FocusTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 21, 2026
- AstraZeneca (AZN) Gets a Buy from RBC CapitalTipRanks Auto-Generated Intelligence Newsdesk · Oct 21, 2026
- AstraZeneca Advances Kidney Failure Strategy With New Hemodialysis Drug StudyTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 20, 2026
- AstraZeneca Completes Real‑World Asthma Biologic Study in ChinaTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 20, 2026
- AstraZeneca Advances Kidney Failure Strategy With New Hemodialysis Drug StudyTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 20, 2026
- AstraZeneca Completes Real‑World Asthma Biologic Study in ChinaTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 20, 2026
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AZN | $184.11 | -0.7% | 297.77K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |